Research programme: apolipoprotein E mimetic peptides - LipimetiX Development

Drug Profile

Research programme: apolipoprotein E mimetic peptides - LipimetiX Development

Alternative Names: AEM 28 02; AEM-28-08; AEM-28-14

Latest Information Update: 14 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Alabama at Birmingham
  • Developer LipimetiX Development
  • Class Peptides
  • Mechanism of Action Apolipoprotein E agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hypercholesterolaemia
  • Research Coronary artery disease; Peripheral arterial disorders

Most Recent Events

  • 07 May 2018 AEM 28 analogues licensed to Anji Pharma in China, Taiwan and Hong Kong
  • 19 Dec 2016 Pharmacodynamics data from preclinial studies inHypercholesterolaemia released by LipimetiX Development
  • 25 Aug 2016 LipimetiX Development plans phase-I and phase-II trials for hypercholesterolemia and hypertriglyceridemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top